Quick Answer
PROVECTUS BIOPHARMACEUTICALS, INC. reported Net Income Loss of -$5.43 million for the year ending 2025.
- PROVECTUS BIOPHARMACEUTICALS, INC. showed a decrease of -14.8% in Net Income Loss from 2024 to 2025.
- This data is from PROVECTUS BIOPHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2005 to 2025 (21 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 21 years of available data (2005 to 2025), PROVECTUS BIOPHARMACEUTICALS, INC.'s Net Income Loss has grown by 53.8%.
- Historical annual values: Fiscal year 2025: -$5.43 million | Fiscal year 2024: -$4.73 million | Fiscal year 2023: -$3.10 million | Fiscal year 2022: -$3.55 million | Fiscal year 2021: -$5.54 million | Fiscal year 2020: -$6.68 million | Fiscal year 2019: -$6.92 million | Fiscal year 2018: -$8.15 million | Fiscal year 2017: -$13.52 million | Fiscal year 2016: -$24.43 million | Fiscal year 2015: -$24.50 million | Fiscal year 2014: -$10.24 million | Fiscal year 2013: -$27.70 million | Fiscal year 2012: -$12.57 million | Fiscal year 2011: -$19.43 million | Fiscal year 2010: -$18.55 million | Fiscal year 2009: -$12.32 million | Fiscal year 2008: -$10.27 million | Fiscal year 2007: -$10.01 million | Fiscal year 2006: -$8.87 million | Fiscal year 2005: -$11.76 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: